First-pass extracted concept

AAV-based gene therapy manufacturing process

Candidate: concept label1 source documents3 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

This review provides a comprehensive framework for establishing robust AAV-based gene therapy manufacturing processes by evaluating industry challenges and recent technological innovations.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1problem statementsupports2025Source 1DOI PubMed

AAV gene therapy translation is constrained by manufacturing challenges including process variability, low yields, and scalability challenges.

Claim 2process frameworksupports2025Source 1DOI PubMed

The paper presents an end-to-end framework for AAV-based gene therapy manufacturing spanning upstream cell culture and transfection through downstream purification and fill-finish operations.

Claim 3workflow prioritysupports2025Source 1DOI PubMed

A quality-by-design framework is central to the AAV-based gene therapy manufacturing process.